Jiangxi Jemincare Group Secures Exclusive Rights to Promote MabPharm’s Biosimilar CMAB007
Jiangxi Jemincare Group, a China-based healthcare company, has entered into a licensing agreement with fellow...
Auto-immune
Priority Review Status Anticipated for HH-003, BI655130, VIS649, and Remternetug by CDE
The Center for Drug Evaluation (CDE) website has indicated that Huahui Health’s HH-003, Boehringer Ingelheim’s...
JW Therapeutics’ Carteyva Receives NMPA Approval for Moderate-to-Severe SLE Clinical Trial
China-based JW Therapeutics (HKG: 2126) has announced receiving tacit clinical trial approval from the National...
Biosion Receives FDA Approval for Phase II Study of TSLP mAb BSI-045B
Global, clinical-stage biotech company Biosion, dedicated to developing antibody-based therapies for immune and oncologic diseases,...
Roche’s Cosentyx 300mg Dosage Approved by NMPA for Ankylosing Spondylitis Treatment
Swiss pharmaceutical giant Roche (SWX: ROG) has announced that the National Medical Products Administration (NMPA)...
Pfizer’s Ritlecitinib Heads for Priority Review in China for Vitiligo Treatment
The China’s Center for Drug Evaluation (CDE) website has indicated that Pfizer’s (NYSE: PFE) ritlecitinib,...
Keymed Biosciences’ CM310 Achieves Primary Endpoints in Phase III Atopic Dermatitis Study
China-based Keymed Biosciences Inc., a prominent player in the biopharmaceutical industry (HKG: 2162), has announced...
CSPC Pharmaceutical Receives NMPA Approval for Generic Otezla Equivalent
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its generic version of Celgene’s...
Chongqing Genrix’s Xeligekimab for Psoriasis Accepted for Market Approval Review
China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that the market approval filing...
Sunshine Guojian Completes Patient Enrollment for SSGJ-611 Phase II Study in Atopic Dermatitis
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has...
Reistone Biopharma’s Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study
Reistone Biopharma Co., Ltd, incubated by Hengrui Pharmaceuticals (SHA: 600276) with USD 100 million in...
Sanofi’s Dupixent Receives Priority Review for Prurigo Nodosa Treatment
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that it has received priority review status...
Novartis’ LNP023 and Janssen’s Tremfya on Track for Breakthrough Designations
The Center for Drug Evaluation (CDE) website indicates that Swiss major Novartis’ (NYSE: NVS) LNP023...
Innovent Biologics Initiates Phase III CLEAR Study for Picankibart in Psoriasis
China-based Innovent Biologics (HKG: 1801) has announced the first subject dosing in the Phase III...
Luye Pharma’s BA2101 Begins Phase I Clinical Trial for Allergic Diseases
China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase...
Hemay Pharma Completes Series D Financing for Autoimmune and Oncology Drugs
China-based Ganzhou Hemay Pharmaceutical Co., Ltd, an innovative drug developer focused on autoimmune diseases and...
CDE Grants Priority Review to Takeda’s Vonicog Alfa, Zhongmei’s Rilonacept, and Zai Lab’s SUL-DUR
The Center for Drug Evaluation (CDE) has indicated that Takeda’s Vonicog alfa, Zhongmei Huadong Pharma’s...
Abbisko’s ABSK021 Gains NMPA Approval for Phase II Study in cGVHD
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving approval from the National...
TechnoDerma Raises Series A+ Funding to Advance Dermatology Pipeline
TechnoDerma Medicines Inc., a Zhejiang-based developer of dermatology small molecules, has reportedly raised “tens of...
Everest Medicines’ Nefecon Receives Priority Review Recommendation from CDE
China-based Everest Medicines (HKG: 1952) has announced that the Center for Drug Evaluation (CDE) of...